Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 19

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 19
---
 domestic or foreign, to change our manufacturing processes
or assays or to perform studies in addition to those that we currently anticipate. Even if we are successful in obtaining additional
regulatory approvals to market our GelrinC or any future product candidates, our revenue earned from such product candidates will be
dependent in part upon the size of the markets in the territories for which we gain regulatory approval for such products, the accepted
price for such products, our ability to obtain reimbursement for such products at any price, whether we own the commercial rights for
that territory in which such products have been approved and the expenses associated with manufacturing and marketing such products for
such markets. Therefore, we may not generate significant revenue from the sale of such products. Further, if we are not able to generate
significant revenue from the sale of our approved products, we may be forced to curtail or cease our operations. Due to the numerous
risks and uncertainties involved in product development, it is difficult to predict the timing or amount of increased expenses, or when,
or if, we will be able to achieve or maintain profitability.

Even if this offering is successful, we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.

As of May 31, 2025, December
31, 2024 and December 31, 2023, our cash and cash equivalents were approximately $0.2 million, $0.2 million and $0.3 million, respectively,
and as of December 31, 2024 and 2023, we had a negative working capital of approximately $6.0 million and $2.8 million, respectively,
and an accumulated deficit of approximately $42.1 million and $46.9 million, respectively. Based on our current plans, we believe that
our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements
through June 2025 without giving effect to the proceeds from this offering. Even if this offering is completed, we expect that we will
require substantial additional capital to commercialize our Gelrin hydrogel platform and any future product candidates. In addition,
our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds
sooner than planned. Our future funding requirements